Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Sep 1;9(1):e2017055.
doi: 10.4084/MJHID.2017.055. eCollection 2017.

Should every Patient with MDS get Iron Chelation - Probably Yes

Kanjaksha Ghosh  1 , Kinjalka Ghosh  2
Affiliations
Comment

Should every Patient with MDS get Iron Chelation - Probably Yes

Kanjaksha Ghosh et al. Mediterr J Hematol Infect Dis. .
No abstract available

Keywords: Anemia; Chelation; Iron Overload; MDS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors have declared that no competing interests exist.

Comment on

  • Myelodysplastic Syndromes and Iron Chelation Therapy.
    Angelucci E, Urru SA, Pilo F, Piperno A. Angelucci E, et al. Mediterr J Hematol Infect Dis. 2017 Mar 1;9(1):e2017021. doi: 10.4084/MJHID.2017.021. eCollection 2017. Mediterr J Hematol Infect Dis. 2017. PMID: 28293409 Free PMC article. Review.

References

    1. Angelucci E, Urru SA, Pilo F, Piperno A. Myelodysplastic Syndromes and Iron Chelation Therapy. Mediterr J Hematol Infect Dis. 2017 Mar 1;9:e2017021. https://doi.org/10.4084/mjhid.2017.021. - DOI - PMC - PubMed
    1. Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study. Br Jr Haematol. 2017;177:741–750. - PubMed
    1. Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, Germing U, Gattermann N. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. Leuk Res. 2012;36:1067–70. https://doi.org/10.1016/j.leukres.2012.04.006. - DOI - PubMed
    1. Shigeta S, Toyoshima M, Kitatani K, Ishibashi M, Usui T, Yaegashi N. Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer. Oncogene. 2016;35:3577–86. https://doi.org/10.1038/onc.2015.425. - DOI - PubMed
    1. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica. 2006;91:1588–90. - PubMed